This poster presentation from Digestive Disease Week 2014 summarizes the results of a study comparing the pharmacokinetic profiles of a single dose of 300 mg iOWH032 in healthy American volunteers, healthy Bangladeshi volunteers, and Bangladeshi cholera patients with severe diarrhea. In addition, the safety of iOWH032 was assessed in these different populations.
Corporate author(s): PATH; International Centre for Diarrhoeal Disease Research, Bangladesh
Publication date: April 2014
201 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Global
- Emerging and epidemic diseases > Drug development
- Maternal and child health > Controlling diarrheal disease
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA